Interferon alpha therapy in essential thrombocythemia and polycythemia vera — A systematic review and meta-analysis Journal Article

   

Authors:	Bewersdorf, J. P.; Giri, S.; Wang, R.; Podoltsev, N.; Williams, R. T.; Tallman, M. S.; Rampal, R. K.; Zeidan, A. M.; Stahl, M.
Article Title:	Interferon alpha therapy in essential thrombocythemia and polycythemia vera — A systematic review and meta-analysis
Abstract:	Data on the efficacy and safety of interferon (IFN)-α for the treatment of essential thrombocythemia (ET) and polycythemia vera (PV) are inconsistent. We conducted a systematic review and meta-analysis and searched MEDLINE and EMBASE via Ovid, Scopus, COCHRANE registry of clinical trials, and Web of Science from inception through 03/2019 for studies of pegylated IFN (peg-IFN) and non-pegylated IFN (non-peg-IFN) in PV and ET patients. Random-effects models were used to pool response rates for the primary outcome of overall response rate (ORR) defined as a composite of complete response, partial response, complete hematologic response (CHR) and partial hematologic response. Peg-IFN and non-peg-IFN were compared by meta-regression analyses. In total, 44 studies with 1359 patients (730 ET, 629 PV) were included. ORR were 80.6% (95% confidence interval: 76.6–84.1%, CHR: 59.0% [51.5%–66.1%]) and 76.7% (67.4–84.0%; CHR: 48.5% [37.8–59.4%]) for ET and PV patients, respectively. In meta-regression analyses results did not differ significantly for non-peg-IFN vs. peg-IFN. Annualized rates of thromboembolic complications and treatment discontinuation due to adverse events were low at 1.2% and 8.8% for ET and 0.5% and 6.5% for PV patients, respectively. Both peg-IFN and non-peg-IFN can be effective and safe long-term treatments for ET and PV. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.
Keywords:	treatment outcome; treatment response; myelofibrosis; histopathology; drug efficacy; drug safety; alpha interferon; follow up; leukopenia; systematic review; thromboembolism; long term care; liver disease; aging; flu like syndrome; neurologic disease; metabolic disorder; treatment withdrawal; meta analysis; polycythemia vera; thrombocythemia; peginterferon alpha; acute myeloid leukemia; complete response; overall response rate; complete hematologic response; human; article; partial response; partial hematologic response
Journal Title:	Leukemia
Volume:	35
Issue:	6
ISSN:	0887-6924
Publisher:	Nature Publishing Group
Date Published:	2021-06-01
Start Page:	1643
End Page:	1660
Language:	English
DOI:	10.1038/s41375-020-01020-4
PUBMED:	32868875
PROVIDER:	scopus
PMCID:	PMC7917159
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089989674&doi=10.1038%2fs41375-020-01020-4&partnerID=40&md5=e2bdf0bbef2a8fa7baa374ed8be4748c
Notes:	Article -- Export Date: 1 July 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/182541